J Vasc Interv Radiol:两年研究结果表明DCB血管成形术对AVFs长期安全且有效

2020-11-15 MedSci原创 MedSci原创

本项随机试验对比了紫杉醇涂层与非涂层球囊血管成形术后血管准备与超高压经皮穿刺血管成形术(PTA)在血液透析动静脉瘘(AVFs)中的2年结果,该研究结果已在线发表于J Vasc Interv Radio

本项随机试验对比了紫杉醇涂层与非涂层球囊血管成形术后血管准备与超高压经皮穿刺血管成形术(PTA)在血液透析动静脉瘘(AVFs)中的2年结果,该研究结果已在线发表于J Vasc Interv Radiol。
研究人员在23个站点招募了285名位于手臂的功能障碍性AVFs受试者。随机分组之前,实现了成功的血管准备(全腰部冲洗,<30%残余狭窄)。
 
最终药物涂层球囊(DCB)组141名受试者中的96人和对照组144名受试者中的111人完成了研究。结果显示,DCB和对照组的目标病变原发通畅率(TLPP)分别为9个月时58%±4 vs 46%±4(P = .02),12个月时44%±5 vs 36%±4(P = .04),18个月时34%±5 vs 28%±4(P = .06),24个月时27%±4 vs 24%±4(P = .09)。受试者发生发生不良反应至TLPP事件的平均时间较DCBs长(322 vs 207 d;P < .0001)。DCB组在9个月(P = .02)时需要较少的干预来维持目标病变的通畅性,但在12个月(P = .08)、18个月(P = .13)或24个月(P = .19)时不需要。所有时间间隔都达到了非劣效性安全目标(P < .01)。组间死亡率无差异(P = .27)。事后分析显示,所有亚组的DCB效果相当。
 
 
综上所述,该两年的结果表明DCB血管成形术对AVFs的长期安全性和疗效。
 
原始出处:
 
Scott O Trerotola, Theodore F Saad, et al., The Lutonix AV Randomized Trial of Paclitaxel-Coated Balloons in Arteriovenous Fistula Stenosis: 2-Year Results and Subgroup Analysis. J Vasc Interv Radiol. 2020 Jan;31(1):1-14.e5. doi: 10.1016/j.jvir.2019.08.035. Epub 2019 Nov 6.
 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1990146, encodeId=341e199014607, content=<a href='/topic/show?id=66308965e00' target=_blank style='color:#2F92EE;'>#血管成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89657, encryptionId=66308965e00, topicName=血管成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Mon Sep 06 15:20:33 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939121, encodeId=e5061939121fd, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Dec 19 13:20:33 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739560, encodeId=72201e3956020, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Wed Oct 06 04:20:33 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005531, encodeId=55152005531d8, content=<a href='/topic/show?id=66fe303e47' target=_blank style='color:#2F92EE;'>#AVF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3037, encryptionId=66fe303e47, topicName=AVF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Mon Dec 07 12:20:33 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004744, encodeId=5ea22004e4431, content=<a href='/topic/show?id=4e8a5400816' target=_blank style='color:#2F92EE;'>#成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54008, encryptionId=4e8a5400816, topicName=成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Wed Aug 04 05:20:33 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1842764, encodeId=689c1842e64f7, content=<a href='/topic/show?id=19ff5e4050' target=_blank style='color:#2F92EE;'>#DCB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5740, encryptionId=19ff5e4050, topicName=DCB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Sep 18 18:20:33 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900123, encodeId=1f8f90012388, content=本项随机试验对比了紫杉醇涂层与非涂层球囊血管成形术后血管准备与超高压经皮穿刺血管成形术(PTA)在血液透析动静脉瘘(AVFs)中的2年结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Wed Nov 18 10:26:01 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900121, encodeId=dc6a90012135, content=DCB血管成形术对AVFs的长期安全性和疗效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Wed Nov 18 10:13:47 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899861, encodeId=3691899861c2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac555424952, createdName=ms8000001754662727, createdTime=Tue Nov 17 14:04:17 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899391, encodeId=e7c0899391fa, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/7778b11aa1b546dbab3dcd70a1fce38f/df95904f81a5499cad7fce1ef96828d6.jpg, createdBy=ff6d5415459, createdName=ms3000000992103323, createdTime=Sun Nov 15 21:58:49 CST 2020, time=2020-11-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1990146, encodeId=341e199014607, content=<a href='/topic/show?id=66308965e00' target=_blank style='color:#2F92EE;'>#血管成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89657, encryptionId=66308965e00, topicName=血管成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Mon Sep 06 15:20:33 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939121, encodeId=e5061939121fd, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Dec 19 13:20:33 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739560, encodeId=72201e3956020, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Wed Oct 06 04:20:33 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005531, encodeId=55152005531d8, content=<a href='/topic/show?id=66fe303e47' target=_blank style='color:#2F92EE;'>#AVF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3037, encryptionId=66fe303e47, topicName=AVF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Mon Dec 07 12:20:33 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004744, encodeId=5ea22004e4431, content=<a href='/topic/show?id=4e8a5400816' target=_blank style='color:#2F92EE;'>#成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54008, encryptionId=4e8a5400816, topicName=成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Wed Aug 04 05:20:33 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1842764, encodeId=689c1842e64f7, content=<a href='/topic/show?id=19ff5e4050' target=_blank style='color:#2F92EE;'>#DCB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5740, encryptionId=19ff5e4050, topicName=DCB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Sep 18 18:20:33 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900123, encodeId=1f8f90012388, content=本项随机试验对比了紫杉醇涂层与非涂层球囊血管成形术后血管准备与超高压经皮穿刺血管成形术(PTA)在血液透析动静脉瘘(AVFs)中的2年结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Wed Nov 18 10:26:01 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900121, encodeId=dc6a90012135, content=DCB血管成形术对AVFs的长期安全性和疗效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Wed Nov 18 10:13:47 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899861, encodeId=3691899861c2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac555424952, createdName=ms8000001754662727, createdTime=Tue Nov 17 14:04:17 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899391, encodeId=e7c0899391fa, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/7778b11aa1b546dbab3dcd70a1fce38f/df95904f81a5499cad7fce1ef96828d6.jpg, createdBy=ff6d5415459, createdName=ms3000000992103323, createdTime=Sun Nov 15 21:58:49 CST 2020, time=2020-11-15, status=1, ipAttribution=)]
    2020-12-19 quxin068
  3. [GetPortalCommentsPageByObjectIdResponse(id=1990146, encodeId=341e199014607, content=<a href='/topic/show?id=66308965e00' target=_blank style='color:#2F92EE;'>#血管成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89657, encryptionId=66308965e00, topicName=血管成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Mon Sep 06 15:20:33 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939121, encodeId=e5061939121fd, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Dec 19 13:20:33 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739560, encodeId=72201e3956020, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Wed Oct 06 04:20:33 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005531, encodeId=55152005531d8, content=<a href='/topic/show?id=66fe303e47' target=_blank style='color:#2F92EE;'>#AVF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3037, encryptionId=66fe303e47, topicName=AVF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Mon Dec 07 12:20:33 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004744, encodeId=5ea22004e4431, content=<a href='/topic/show?id=4e8a5400816' target=_blank style='color:#2F92EE;'>#成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54008, encryptionId=4e8a5400816, topicName=成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Wed Aug 04 05:20:33 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1842764, encodeId=689c1842e64f7, content=<a href='/topic/show?id=19ff5e4050' target=_blank style='color:#2F92EE;'>#DCB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5740, encryptionId=19ff5e4050, topicName=DCB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Sep 18 18:20:33 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900123, encodeId=1f8f90012388, content=本项随机试验对比了紫杉醇涂层与非涂层球囊血管成形术后血管准备与超高压经皮穿刺血管成形术(PTA)在血液透析动静脉瘘(AVFs)中的2年结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Wed Nov 18 10:26:01 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900121, encodeId=dc6a90012135, content=DCB血管成形术对AVFs的长期安全性和疗效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Wed Nov 18 10:13:47 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899861, encodeId=3691899861c2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac555424952, createdName=ms8000001754662727, createdTime=Tue Nov 17 14:04:17 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899391, encodeId=e7c0899391fa, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/7778b11aa1b546dbab3dcd70a1fce38f/df95904f81a5499cad7fce1ef96828d6.jpg, createdBy=ff6d5415459, createdName=ms3000000992103323, createdTime=Sun Nov 15 21:58:49 CST 2020, time=2020-11-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1990146, encodeId=341e199014607, content=<a href='/topic/show?id=66308965e00' target=_blank style='color:#2F92EE;'>#血管成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89657, encryptionId=66308965e00, topicName=血管成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Mon Sep 06 15:20:33 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939121, encodeId=e5061939121fd, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Dec 19 13:20:33 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739560, encodeId=72201e3956020, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Wed Oct 06 04:20:33 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005531, encodeId=55152005531d8, content=<a href='/topic/show?id=66fe303e47' target=_blank style='color:#2F92EE;'>#AVF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3037, encryptionId=66fe303e47, topicName=AVF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Mon Dec 07 12:20:33 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004744, encodeId=5ea22004e4431, content=<a href='/topic/show?id=4e8a5400816' target=_blank style='color:#2F92EE;'>#成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54008, encryptionId=4e8a5400816, topicName=成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Wed Aug 04 05:20:33 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1842764, encodeId=689c1842e64f7, content=<a href='/topic/show?id=19ff5e4050' target=_blank style='color:#2F92EE;'>#DCB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5740, encryptionId=19ff5e4050, topicName=DCB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Sep 18 18:20:33 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900123, encodeId=1f8f90012388, content=本项随机试验对比了紫杉醇涂层与非涂层球囊血管成形术后血管准备与超高压经皮穿刺血管成形术(PTA)在血液透析动静脉瘘(AVFs)中的2年结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Wed Nov 18 10:26:01 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900121, encodeId=dc6a90012135, content=DCB血管成形术对AVFs的长期安全性和疗效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Wed Nov 18 10:13:47 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899861, encodeId=3691899861c2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac555424952, createdName=ms8000001754662727, createdTime=Tue Nov 17 14:04:17 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899391, encodeId=e7c0899391fa, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/7778b11aa1b546dbab3dcd70a1fce38f/df95904f81a5499cad7fce1ef96828d6.jpg, createdBy=ff6d5415459, createdName=ms3000000992103323, createdTime=Sun Nov 15 21:58:49 CST 2020, time=2020-11-15, status=1, ipAttribution=)]
    2020-12-07 xiaoyang_ambs
  5. [GetPortalCommentsPageByObjectIdResponse(id=1990146, encodeId=341e199014607, content=<a href='/topic/show?id=66308965e00' target=_blank style='color:#2F92EE;'>#血管成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89657, encryptionId=66308965e00, topicName=血管成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Mon Sep 06 15:20:33 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939121, encodeId=e5061939121fd, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Dec 19 13:20:33 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739560, encodeId=72201e3956020, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Wed Oct 06 04:20:33 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005531, encodeId=55152005531d8, content=<a href='/topic/show?id=66fe303e47' target=_blank style='color:#2F92EE;'>#AVF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3037, encryptionId=66fe303e47, topicName=AVF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Mon Dec 07 12:20:33 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004744, encodeId=5ea22004e4431, content=<a href='/topic/show?id=4e8a5400816' target=_blank style='color:#2F92EE;'>#成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54008, encryptionId=4e8a5400816, topicName=成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Wed Aug 04 05:20:33 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1842764, encodeId=689c1842e64f7, content=<a href='/topic/show?id=19ff5e4050' target=_blank style='color:#2F92EE;'>#DCB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5740, encryptionId=19ff5e4050, topicName=DCB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Sep 18 18:20:33 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900123, encodeId=1f8f90012388, content=本项随机试验对比了紫杉醇涂层与非涂层球囊血管成形术后血管准备与超高压经皮穿刺血管成形术(PTA)在血液透析动静脉瘘(AVFs)中的2年结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Wed Nov 18 10:26:01 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900121, encodeId=dc6a90012135, content=DCB血管成形术对AVFs的长期安全性和疗效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Wed Nov 18 10:13:47 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899861, encodeId=3691899861c2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac555424952, createdName=ms8000001754662727, createdTime=Tue Nov 17 14:04:17 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899391, encodeId=e7c0899391fa, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/7778b11aa1b546dbab3dcd70a1fce38f/df95904f81a5499cad7fce1ef96828d6.jpg, createdBy=ff6d5415459, createdName=ms3000000992103323, createdTime=Sun Nov 15 21:58:49 CST 2020, time=2020-11-15, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1990146, encodeId=341e199014607, content=<a href='/topic/show?id=66308965e00' target=_blank style='color:#2F92EE;'>#血管成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89657, encryptionId=66308965e00, topicName=血管成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Mon Sep 06 15:20:33 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939121, encodeId=e5061939121fd, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Dec 19 13:20:33 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739560, encodeId=72201e3956020, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Wed Oct 06 04:20:33 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005531, encodeId=55152005531d8, content=<a href='/topic/show?id=66fe303e47' target=_blank style='color:#2F92EE;'>#AVF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3037, encryptionId=66fe303e47, topicName=AVF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Mon Dec 07 12:20:33 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004744, encodeId=5ea22004e4431, content=<a href='/topic/show?id=4e8a5400816' target=_blank style='color:#2F92EE;'>#成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54008, encryptionId=4e8a5400816, topicName=成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Wed Aug 04 05:20:33 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1842764, encodeId=689c1842e64f7, content=<a href='/topic/show?id=19ff5e4050' target=_blank style='color:#2F92EE;'>#DCB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5740, encryptionId=19ff5e4050, topicName=DCB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Sep 18 18:20:33 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900123, encodeId=1f8f90012388, content=本项随机试验对比了紫杉醇涂层与非涂层球囊血管成形术后血管准备与超高压经皮穿刺血管成形术(PTA)在血液透析动静脉瘘(AVFs)中的2年结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Wed Nov 18 10:26:01 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900121, encodeId=dc6a90012135, content=DCB血管成形术对AVFs的长期安全性和疗效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Wed Nov 18 10:13:47 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899861, encodeId=3691899861c2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac555424952, createdName=ms8000001754662727, createdTime=Tue Nov 17 14:04:17 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899391, encodeId=e7c0899391fa, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/7778b11aa1b546dbab3dcd70a1fce38f/df95904f81a5499cad7fce1ef96828d6.jpg, createdBy=ff6d5415459, createdName=ms3000000992103323, createdTime=Sun Nov 15 21:58:49 CST 2020, time=2020-11-15, status=1, ipAttribution=)]
    2021-09-18 quxin068
  7. [GetPortalCommentsPageByObjectIdResponse(id=1990146, encodeId=341e199014607, content=<a href='/topic/show?id=66308965e00' target=_blank style='color:#2F92EE;'>#血管成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89657, encryptionId=66308965e00, topicName=血管成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Mon Sep 06 15:20:33 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939121, encodeId=e5061939121fd, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Dec 19 13:20:33 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739560, encodeId=72201e3956020, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Wed Oct 06 04:20:33 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005531, encodeId=55152005531d8, content=<a href='/topic/show?id=66fe303e47' target=_blank style='color:#2F92EE;'>#AVF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3037, encryptionId=66fe303e47, topicName=AVF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Mon Dec 07 12:20:33 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004744, encodeId=5ea22004e4431, content=<a href='/topic/show?id=4e8a5400816' target=_blank style='color:#2F92EE;'>#成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54008, encryptionId=4e8a5400816, topicName=成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Wed Aug 04 05:20:33 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1842764, encodeId=689c1842e64f7, content=<a href='/topic/show?id=19ff5e4050' target=_blank style='color:#2F92EE;'>#DCB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5740, encryptionId=19ff5e4050, topicName=DCB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Sep 18 18:20:33 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900123, encodeId=1f8f90012388, content=本项随机试验对比了紫杉醇涂层与非涂层球囊血管成形术后血管准备与超高压经皮穿刺血管成形术(PTA)在血液透析动静脉瘘(AVFs)中的2年结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Wed Nov 18 10:26:01 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900121, encodeId=dc6a90012135, content=DCB血管成形术对AVFs的长期安全性和疗效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Wed Nov 18 10:13:47 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899861, encodeId=3691899861c2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac555424952, createdName=ms8000001754662727, createdTime=Tue Nov 17 14:04:17 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899391, encodeId=e7c0899391fa, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/7778b11aa1b546dbab3dcd70a1fce38f/df95904f81a5499cad7fce1ef96828d6.jpg, createdBy=ff6d5415459, createdName=ms3000000992103323, createdTime=Sun Nov 15 21:58:49 CST 2020, time=2020-11-15, status=1, ipAttribution=)]
    2020-11-18 咻凡

    本项随机试验对比了紫杉醇涂层与非涂层球囊血管成形术后血管准备与超高压经皮穿刺血管成形术(PTA)在血液透析动静脉瘘(AVFs)中的2年结果

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1990146, encodeId=341e199014607, content=<a href='/topic/show?id=66308965e00' target=_blank style='color:#2F92EE;'>#血管成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89657, encryptionId=66308965e00, topicName=血管成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Mon Sep 06 15:20:33 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939121, encodeId=e5061939121fd, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Dec 19 13:20:33 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739560, encodeId=72201e3956020, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Wed Oct 06 04:20:33 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005531, encodeId=55152005531d8, content=<a href='/topic/show?id=66fe303e47' target=_blank style='color:#2F92EE;'>#AVF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3037, encryptionId=66fe303e47, topicName=AVF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Mon Dec 07 12:20:33 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004744, encodeId=5ea22004e4431, content=<a href='/topic/show?id=4e8a5400816' target=_blank style='color:#2F92EE;'>#成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54008, encryptionId=4e8a5400816, topicName=成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Wed Aug 04 05:20:33 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1842764, encodeId=689c1842e64f7, content=<a href='/topic/show?id=19ff5e4050' target=_blank style='color:#2F92EE;'>#DCB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5740, encryptionId=19ff5e4050, topicName=DCB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Sep 18 18:20:33 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900123, encodeId=1f8f90012388, content=本项随机试验对比了紫杉醇涂层与非涂层球囊血管成形术后血管准备与超高压经皮穿刺血管成形术(PTA)在血液透析动静脉瘘(AVFs)中的2年结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Wed Nov 18 10:26:01 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900121, encodeId=dc6a90012135, content=DCB血管成形术对AVFs的长期安全性和疗效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Wed Nov 18 10:13:47 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899861, encodeId=3691899861c2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac555424952, createdName=ms8000001754662727, createdTime=Tue Nov 17 14:04:17 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899391, encodeId=e7c0899391fa, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/7778b11aa1b546dbab3dcd70a1fce38f/df95904f81a5499cad7fce1ef96828d6.jpg, createdBy=ff6d5415459, createdName=ms3000000992103323, createdTime=Sun Nov 15 21:58:49 CST 2020, time=2020-11-15, status=1, ipAttribution=)]
    2020-11-18 咻凡

    DCB血管成形术对AVFs的长期安全性和疗效。

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1990146, encodeId=341e199014607, content=<a href='/topic/show?id=66308965e00' target=_blank style='color:#2F92EE;'>#血管成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89657, encryptionId=66308965e00, topicName=血管成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Mon Sep 06 15:20:33 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939121, encodeId=e5061939121fd, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Dec 19 13:20:33 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739560, encodeId=72201e3956020, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Wed Oct 06 04:20:33 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005531, encodeId=55152005531d8, content=<a href='/topic/show?id=66fe303e47' target=_blank style='color:#2F92EE;'>#AVF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3037, encryptionId=66fe303e47, topicName=AVF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Mon Dec 07 12:20:33 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004744, encodeId=5ea22004e4431, content=<a href='/topic/show?id=4e8a5400816' target=_blank style='color:#2F92EE;'>#成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54008, encryptionId=4e8a5400816, topicName=成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Wed Aug 04 05:20:33 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1842764, encodeId=689c1842e64f7, content=<a href='/topic/show?id=19ff5e4050' target=_blank style='color:#2F92EE;'>#DCB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5740, encryptionId=19ff5e4050, topicName=DCB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Sep 18 18:20:33 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900123, encodeId=1f8f90012388, content=本项随机试验对比了紫杉醇涂层与非涂层球囊血管成形术后血管准备与超高压经皮穿刺血管成形术(PTA)在血液透析动静脉瘘(AVFs)中的2年结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Wed Nov 18 10:26:01 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900121, encodeId=dc6a90012135, content=DCB血管成形术对AVFs的长期安全性和疗效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Wed Nov 18 10:13:47 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899861, encodeId=3691899861c2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac555424952, createdName=ms8000001754662727, createdTime=Tue Nov 17 14:04:17 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899391, encodeId=e7c0899391fa, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/7778b11aa1b546dbab3dcd70a1fce38f/df95904f81a5499cad7fce1ef96828d6.jpg, createdBy=ff6d5415459, createdName=ms3000000992103323, createdTime=Sun Nov 15 21:58:49 CST 2020, time=2020-11-15, status=1, ipAttribution=)]
    2020-11-17 ms8000001754662727

    学习了

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1990146, encodeId=341e199014607, content=<a href='/topic/show?id=66308965e00' target=_blank style='color:#2F92EE;'>#血管成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89657, encryptionId=66308965e00, topicName=血管成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Mon Sep 06 15:20:33 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939121, encodeId=e5061939121fd, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Dec 19 13:20:33 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739560, encodeId=72201e3956020, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Wed Oct 06 04:20:33 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005531, encodeId=55152005531d8, content=<a href='/topic/show?id=66fe303e47' target=_blank style='color:#2F92EE;'>#AVF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3037, encryptionId=66fe303e47, topicName=AVF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Mon Dec 07 12:20:33 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004744, encodeId=5ea22004e4431, content=<a href='/topic/show?id=4e8a5400816' target=_blank style='color:#2F92EE;'>#成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54008, encryptionId=4e8a5400816, topicName=成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Wed Aug 04 05:20:33 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1842764, encodeId=689c1842e64f7, content=<a href='/topic/show?id=19ff5e4050' target=_blank style='color:#2F92EE;'>#DCB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5740, encryptionId=19ff5e4050, topicName=DCB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Sep 18 18:20:33 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900123, encodeId=1f8f90012388, content=本项随机试验对比了紫杉醇涂层与非涂层球囊血管成形术后血管准备与超高压经皮穿刺血管成形术(PTA)在血液透析动静脉瘘(AVFs)中的2年结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Wed Nov 18 10:26:01 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900121, encodeId=dc6a90012135, content=DCB血管成形术对AVFs的长期安全性和疗效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Wed Nov 18 10:13:47 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899861, encodeId=3691899861c2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac555424952, createdName=ms8000001754662727, createdTime=Tue Nov 17 14:04:17 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899391, encodeId=e7c0899391fa, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/7778b11aa1b546dbab3dcd70a1fce38f/df95904f81a5499cad7fce1ef96828d6.jpg, createdBy=ff6d5415459, createdName=ms3000000992103323, createdTime=Sun Nov 15 21:58:49 CST 2020, time=2020-11-15, status=1, ipAttribution=)]
    2020-11-15 ms3000000992103323

    谢谢分享

    0

相关资讯

Prostate:去势抵抗性前列腺癌中雄激素受体信号靶向治疗和紫杉醇化疗能够诱导内脏转移

内脏转移(VM)是前列腺癌(PC)的一个重要的不良预后因素,在去势敏感状态下不常见,但在去势抗性产生后经常观察到。然而,VM的部位、出现时间和发生率还未完全阐明。

紫杉醇致扁平苔藓样药疹1例

患者女,62 岁,双下肢红斑、丘疹伴痒 2 个月, 加重伴全身泛发 1 个月。患者入院前 2 个月无明显 诱因双下肢出现红斑、丘疹,瘙痒明显,1 个月前皮 疹泛发至全身,双下肢肿胀明显,为求进一步诊治

J Clin Oncol:辅助紫杉醇和曲妥珠单抗试验治疗结节阴性、人表皮生长因子受体2阳性乳腺癌的七年随访分析

紫杉醇和曲妥珠单抗辅助试验旨在解决人类小表皮生长因子受体2(HER2)阳性乳腺癌患者的治疗问题。辅助紫杉醇和曲妥珠单抗试验的主要分析表明,3年无病生存期(DFS)为98.7%。在这项计划中的二级分析中

NEJM:药物涂层球囊用于预防功能失调性动静脉瘘术后再狭窄

在功能失调性动静脉瘘狭窄性病变术后接受紫杉醇药物涂层球囊抗逆转录治疗可改善患者预后,提高血管通畅率

罗氏Tecentriq联合紫杉醇用于三阴性乳腺癌研究主要终点PFS未能达到

罗氏今日宣布,抗PD-L1抗体Tecentriq(atezolizumab)与紫杉醇联合治疗转移性三阴性乳腺癌(TNBC)的III期临床试验(IMpassion131研究)未能显著改善PFS。

Lancet:紫杉醇是不发达地区晚期卡波西肉瘤的**方案

紫杉醇联合抗逆转录病毒治疗是不发达地区HIV相关卡波西肉瘤的一线治疗选择